A
SUPN icon

Argentarii’s Supernus Pharmaceuticals SUPN Stock Holding History

Argentarii’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Hold
7,500
– – 0.11% 158
2026
Q1 		$388K Hold
7,500
– – 0.14% 136
2025
Q4 		$373K Hold
7,500
– – 0.12% 139
2025
Q3 		$358K Hold
7,500
– – 0.14% 112
2025
Q2 		$236K Hold
7,500
– – 0.11% 139
2025
Q1 		$246K Hold
7,500
– – 0.12% 138
2024
Q4 		$271K Buy
+7,500
New +$264K 0.14% 125

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Argentarii's SUPN Position: Q2 2026 in Review

Argentarii held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 7,500 shares worth $352K. The position accounts for 0.11% of the portfolio, ranked #158.

Argentarii first reported a position in SUPN in Q4 2024 and has held it in 7 quarters since. The position peaked at $388K in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Argentarii held 7,500 shares of Supernus Pharmaceuticals worth $352K as of Q2 2026.
  • Argentarii left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up 0.11% of Argentarii's portfolio in Q2 2026, its #158 holding.
  • Argentarii first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Argentarii's Supernus Pharmaceuticals position peaked at $388K in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Argentarii's 13F filing for Q2 2026, filed 12 Aug 2026.